T. Rothe (Davos Wolfgang, Switzerland), R. W. Dal Negro (Verona, Italy)
Change in airway inflammation during 1 year of specific immunotherapy
T. Knudsen, J. Arnved, V. Backer (Copenhagen, Denmark)
|  |
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
M. Shameem, N. N. Shah, A. A. Bachh, R. Bhargava, Z. Ahmed, Q. Syed, K. A. Dar, I. Haq (Srinagar, J&K, Aligarh, Uttar Pradesh, India)
|  |
Characterization of asthma exacerbations by Arg16Gly genotype in subjects with asthma receiving salmeterol alone or with fluticasone propionate
H. Nelson, E. Bleecker, J. Corren, S. Yancey, D. Reilly, A. Emmett, W. Anderson, H. Ortega (Denver, CO, Winston Salem, NC, Los Angeles, CA, Research Triangle Park, NC, United States Of America)
| |
Lack of effect of promoter, coding and 3‘ polymorphisms of the β2-adrenergic receptor (ADRB2) on the clinical response to salmeterol alone or with fluticasone propionate in subjects with asthma
W. Anderson, E. Bleecker, H. Nelson, J. Corren, A. Emmett, D. Reilly, S. Yancey, H. Ortega (Research Triangle Park, NC, Winston Salem, NC, Denver, CO, Los Angeles, CA, United States Of America)
| |
Omalizumab (Xolair®) reduces exacerbations in adolescents more than in adults with allergic (IgE-mediated) asthma: a subgroup analysis of pooled clinical trials
B. Lanier, F. Albers, I. Berhane, P. Jimenez (Texas, East Hanover, United States Of America)
| |
Identifying patients with severe allergic asthma who are potentially eligible for omalizumab treatment by EU licence and NICE guidance criteria
A. Mistry, E. Watkins, M. Britton, M. Nordstrom (Surrey, United Kingdom)
| |
Novel omalizumab liquid formulation bioequivalent to lyophilized formulation
G. J. Riviere, P. Kuebler, J. Jaffe, C. M. Yeh, C. Reynolds, L. Brookman (East Hanover, San Francisco, United States Of America; Horsham, United Kingdom)
| |
Relationship between pre-treatment specific IgE and the response to omalizumab therapy
U. Wahn, C. Martin, P. Freeman, M. Blogg, P. Jimenez (Berlin, Germany; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Omalizumab (Xolair®) reduces exacerbations in patients with moderate-to-severe persistent allergic asthma independent of former smoking status
D. Price, M. Blogg, F. Albers, P. Jimenez (Aberdeen, Horsham, United Kingdom; East Hanover, United States Of America)
| |
Effects of omalizumab in asthmatic patients with neurodermatitis
P. Velling, S. Pabst, D. Skowasch, C. Grohé (Bonn, Berlin, Germany)
| |
The Anglo-French real-life experience of maintenance OCS use in omalizumab-treated patients with severe persistent allergic asthma
M. Molimard, R. Niven, V. Le Gros, D. McBryan, Z. Panahloo, J. Thirlwell (Bordeaux, Rueil-Malmaison, France; Manchester, Frimley, Horsham, United Kingdom)
| |
Relationship between omalizumab pharmacokinetics (PK), IgE pharmacodynamics (PD) and clinical symptoms in patients with severe persistent allergic asthma
P. Lowe, S. Tannenbaum, A. Gautier, P. Jimenez, Z. Panahloo (Basel, Switzerland; East Hanover, United States Of America; Horsham, United Kingdom)
| |
Treatment of uncontrolled, severe persistent allergic (IgE-mediated) asthma with omalizumab in a real-life setting in Germany
S. Korn, A. Thielen, S. Seyfried, O. Kornmann, R. Buhl (Mainz, Nuremberg, Germany)
| |
Use of a protocol to select patients for omalizumab treatment
H. McLoughlin, A. Hart-Thomas, J. Slough, T. Capstick (Leeds, United Kingdom)
| |
Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma
R. Kaushik, B. Menon, V. K. Vijayan, R. Kulshrestha (New Delhi, India)
| |
Supplementation with omega-3 fatty acids and atopy symptoms in infants: a randomized controlled trial
I. Romieu, A. Barraza-Villarreal, L. Hernández-Cadena, C. Escamilla-Nuñez, P. Sly, L. Neulfeld, J. Rivera, U. Ramkrishnan (Cuernavaca, Morelos, Mexico; West Perth, WA, Australia; Atlanta, GA, United States Of America)
| |
Safety and immunogenicity of hemophilus influenzae type B conjugate vaccine in COPD
N. S. Reddy, M. Khan, N. Methuku, S. Bodi, Aleem (Hyderabad, India)
| |
Comparison of two intranasal triamcinolone acetonide formulations in patients with seasonal or perennial allergic rhinitis
B. Basavaraj, A. Pherwani, N. Prasad, M. S. Shete, C. J. Po, S. Chachad, S. Purandare, G. Malhotra, A. Lulla (Mysore, Mumbai, Bangalore, India)
| |
Antioxidant treatment alters the immune response in resistive breathing
P. Katsaounou, D. Toumpanakis, M. Karatza, X. Roussos, S. Zakynthinos, T. Vassilakopoulos (Athens, Greece)
| |
Reduction of treatment time for nebulized treatments using a new adaptive aerosol delivery mode
I. Prince, A. Black, C. Smart, K. Nikander, T. Dyche, J. Denyer (Chichester, United Kingdom; Parsippany, NJ, United States Of America)
| |